Company Profile

Industry Sector: Audiological Medical Devices

Company Overview:
Mimosa Acoustics manufactures state-of-the-art auditory diagnostic systems for evaluating middle and inner-ear health.

Target Market(s):
- Equipment for mandatory hearing screening
- Hospitals, clinics, & birthing centers
- Hearing specialists (audiologists, otolaryngologists)
- Pediatricians & general practitioners
- School & occupational safety screening programs
- Audiological research & education institutions

Management

Leadership:
Pat Jeng, Ph.D., President
Jont Allen, Ph.D., Chief Technology Officer
Joseph Jeng, Director
Andrew C. Singer, Ph.D., Director

Closely held private company.
Pat Jeng & Jont Allen are recognized leaders within the audiological research community.

Key Value Drivers

Technology:
Mimosa Acoustics possesses the only FDA-approved device for wide band frequency analysis of the middle ear.

Competitive Advantage:
Mimosa Acoustics’ patented diagnostic system is the only available method for obtaining diagnostic data about both the middle- and inner ear in a single test. Non-invasive testing takes only seconds and requires no patient response, meaning that it can be used on patients of all ages. Unlike widely-used tympanometry, Mimosa’s test provides data across the broad speech frequency range and can be used for patients with ear tubes or painlessly on inflamed middle ears.

Plan & Strategy:
Mimosa has commenced an aggressive business development campaign in order to commercialize its technology.

Product Development

FDA approved and commercially available since October 2006.

Single technology platform with multiple testing modules in any combination
- Middle Ear:
  - Middle Ear Power Analysis (MEPA)
- Inner Ear:
  - Distortion Product Otoacoustic Emissions (DPOAE)
  - Transient Evoked Otoacoustic Emissions (TEOAE)